vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and Origin Bancorp, Inc. (OBK). Click either name above to swap in a different company.
Amphastar Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($183.1M vs $104.0M, roughly 1.8× Origin Bancorp, Inc.). Origin Bancorp, Inc. runs the higher net margin — 26.6% vs 13.3%, a 13.3% gap on every dollar of revenue. Over the past eight quarters, Origin Bancorp, Inc.'s revenue compounded faster (3.9% CAGR vs 3.2%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
Southern Bancorp is a community development financial institution headquartered in Arkadelphia, Arkansas. It was founded in 1986 as Southern Development Bancorporation, and is often referred to simply as "Southern".
AMPH vs OBK — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $104.0M |
| Net Profit | $24.4M | $27.7M |
| Gross Margin | 46.8% | — |
| Operating Margin | 19.4% | — |
| Net Margin | 13.3% | 26.6% |
| Revenue YoY | -1.8% | — |
| Net Profit YoY | -35.7% | — |
| EPS (diluted) | $0.51 | $0.89 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $104.0M | ||
| Q4 25 | $183.1M | $103.4M | ||
| Q3 25 | $191.8M | $109.8M | ||
| Q2 25 | $174.4M | $83.5M | ||
| Q1 25 | $170.5M | $94.1M | ||
| Q4 24 | $186.5M | $78.3M | ||
| Q3 24 | $191.2M | $90.8M | ||
| Q2 24 | $182.4M | $96.4M |
| Q1 26 | — | $27.7M | ||
| Q4 25 | $24.4M | $29.5M | ||
| Q3 25 | $17.4M | $8.6M | ||
| Q2 25 | $31.0M | $14.6M | ||
| Q1 25 | $25.3M | $22.4M | ||
| Q4 24 | $38.0M | $14.3M | ||
| Q3 24 | $40.4M | $18.6M | ||
| Q2 24 | $37.9M | $21.0M |
| Q1 26 | — | — | ||
| Q4 25 | 46.8% | — | ||
| Q3 25 | 51.4% | — | ||
| Q2 25 | 49.6% | — | ||
| Q1 25 | 50.0% | — | ||
| Q4 24 | 46.5% | — | ||
| Q3 24 | 53.3% | — | ||
| Q2 24 | 52.2% | — |
| Q1 26 | — | — | ||
| Q4 25 | 19.4% | 36.2% | ||
| Q3 25 | 13.2% | 10.0% | ||
| Q2 25 | 24.2% | 22.3% | ||
| Q1 25 | 21.9% | 30.4% | ||
| Q4 24 | 24.2% | 23.0% | ||
| Q3 24 | 29.8% | 26.1% | ||
| Q2 24 | 30.3% | 27.7% |
| Q1 26 | — | 26.6% | ||
| Q4 25 | 13.3% | 28.5% | ||
| Q3 25 | 9.0% | 7.9% | ||
| Q2 25 | 17.8% | 17.5% | ||
| Q1 25 | 14.8% | 23.8% | ||
| Q4 24 | 20.4% | 18.2% | ||
| Q3 24 | 21.1% | 20.5% | ||
| Q2 24 | 20.8% | 21.8% |
| Q1 26 | — | $0.89 | ||
| Q4 25 | $0.51 | $0.95 | ||
| Q3 25 | $0.37 | $0.27 | ||
| Q2 25 | $0.64 | $0.47 | ||
| Q1 25 | $0.51 | $0.71 | ||
| Q4 24 | $0.74 | $0.45 | ||
| Q3 24 | $0.78 | $0.60 | ||
| Q2 24 | $0.73 | $0.67 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | — |
| Total DebtLower is stronger | $608.7M | — |
| Stockholders' EquityBook value | $788.8M | $1.3B |
| Total Assets | $1.6B | $10.2B |
| Debt / EquityLower = less leverage | 0.77× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $282.8M | $424.2M | ||
| Q3 25 | $276.2M | $626.9M | ||
| Q2 25 | $231.8M | $334.1M | ||
| Q1 25 | $236.9M | $486.2M | ||
| Q4 24 | $221.6M | $470.2M | ||
| Q3 24 | $250.5M | $321.2M | ||
| Q2 24 | $217.8M | $288.1M |
| Q1 26 | — | — | ||
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — |
| Q1 26 | — | $1.3B | ||
| Q4 25 | $788.8M | $1.2B | ||
| Q3 25 | $776.7M | $1.2B | ||
| Q2 25 | $757.5M | $1.2B | ||
| Q1 25 | $751.3M | $1.2B | ||
| Q4 24 | $732.3M | $1.1B | ||
| Q3 24 | $727.7M | $1.1B | ||
| Q2 24 | $713.3M | $1.1B |
| Q1 26 | — | $10.2B | ||
| Q4 25 | $1.6B | $9.7B | ||
| Q3 25 | $1.7B | $9.8B | ||
| Q2 25 | $1.6B | $9.7B | ||
| Q1 25 | $1.6B | $9.8B | ||
| Q4 24 | $1.6B | $9.7B | ||
| Q3 24 | $1.5B | $10.0B | ||
| Q2 24 | $1.5B | $9.9B |
| Q1 26 | — | — | ||
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | — |
| Free Cash FlowOCF − Capex | $24.6M | — |
| FCF MarginFCF / Revenue | 13.4% | — |
| Capex IntensityCapex / Revenue | 4.5% | — |
| Cash ConversionOCF / Net Profit | 1.35× | — |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $32.9M | $158.9M | ||
| Q3 25 | $52.6M | $59.3M | ||
| Q2 25 | $35.6M | $20.6M | ||
| Q1 25 | $35.1M | $35.6M | ||
| Q4 24 | $29.0M | $108.5M | ||
| Q3 24 | $60.0M | $39.6M | ||
| Q2 24 | $69.1M | $11.9M |
| Q1 26 | — | — | ||
| Q4 25 | $24.6M | $151.1M | ||
| Q3 25 | $47.2M | $56.8M | ||
| Q2 25 | $25.0M | $19.6M | ||
| Q1 25 | $24.4M | $34.8M | ||
| Q4 24 | $16.6M | $86.4M | ||
| Q3 24 | $46.2M | $32.2M | ||
| Q2 24 | $63.1M | $6.5M |
| Q1 26 | — | — | ||
| Q4 25 | 13.4% | 146.0% | ||
| Q3 25 | 24.6% | 51.7% | ||
| Q2 25 | 14.3% | 23.5% | ||
| Q1 25 | 14.3% | 37.0% | ||
| Q4 24 | 8.9% | 110.3% | ||
| Q3 24 | 24.1% | 35.5% | ||
| Q2 24 | 34.6% | 6.8% |
| Q1 26 | — | — | ||
| Q4 25 | 4.5% | 7.6% | ||
| Q3 25 | 2.8% | 2.3% | ||
| Q2 25 | 6.1% | 1.2% | ||
| Q1 25 | 6.3% | 0.8% | ||
| Q4 24 | 6.7% | 28.1% | ||
| Q3 24 | 7.2% | 8.1% | ||
| Q2 24 | 3.3% | 5.6% |
| Q1 26 | — | — | ||
| Q4 25 | 1.35× | 5.38× | ||
| Q3 25 | 3.03× | 6.88× | ||
| Q2 25 | 1.15× | 1.41× | ||
| Q1 25 | 1.39× | 1.59× | ||
| Q4 24 | 0.76× | 7.60× | ||
| Q3 24 | 1.48× | 2.13× | ||
| Q2 24 | 1.82× | 0.57× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
OBK
| Net Interest Income | $87.2M | 84% |
| Noninterest Income | $16.8M | 16% |
